EIKON Group

https://www.eikon.group
https://www.linkedin.com/company/eikon-group/

EIKON Group is a privately owned UK-based company founded in 2014. Employing approximately 210 people, it provides broadcast professional services specializing in post-production, localization, and mastering. In 2023, the company's revenue was less than $25 million.

2024 Revenue

Founded

2014

Headcount

203

Headquarters

Primary Segment

Media managed services

Ownership

Privately Owned

Deployments

News Summary:

The Eikon Exhibition Centre hosted a panel debate on finance and funding on an unspecified date, where Alliance party MLA for Lagan Valley Honeyford noted the innovation displayed by local firms. A study used Eikon data, alongside data from RobecoSAM and Sustainalytics, to investigate how ESG rating divergences and climate transition risks affect portfolio performance for 389 US firms across ten sectors. The Eikon Exhibition Centre will also host the Northern Ireland Manufacturing and Supply Chain Conference & Exhibition on September 11th. Finally, unrelated news reports that Franz Richter was confirmed as a member of the Meyer Burger board of directors until June 30th, 2026.

Similar Companies

Subscribe for full access to EIKON Group's profile

EIKON Group offers 9 products in the media tech industry. EIKON Group's product portfolio comprises of content supply chain, production and post production, media cloud and storage and media managed services.

Subscribe for full access to EIKON Group's products in full detail

EIKON Group's revenues were less than $50M in 2024. Caretta Research has split EIKON Group's revenue into 8 different product categories, the largest of which is localisation and access services. For full access to EIKON Group's revenue breakdown subscribe to Caretta Portal.

Subscribe for full access to EIKON Group's revenue in full detail

Dec

2nd

2025

18:30

B2B Tag

Appointments and advancements for Dec. 3, 2025

New hires and promotions in the biopharma industry, including: Adarx, ALK-Abello, Alkeus, Comanche, Eikon, Ernexa, Ovid, Palisade, Strand, Tacalyx, Trimtech, Ventyx.

BioWorld

Nov

4th

2025

23:51

CT_Monitor Company

Novel TLR Coagonist Combo Shows Responses in Stage IV NSCLC

Encouraging clinical activity was reported in patients with stage IV non–small cell lung cancer (NSCLC) who received ELK1001, an investigational toll-like receptor (TLR) 7/8 coagonist, plus pembrolizumab (Keytruda), according to a presentation on findings from the phase 2 TeLuRide-005 trial (NCT06246110) at the European Society for Medical Oncology (ESMO) Congress 2025 .1 The results indicated that the objective response rate (ORR) was 64% (95% CI, 41%-75%) among 50 evaluable patients.

Cancer Network (US)

Oct

28th

2025

17:50

Operational Challenges

Local tattoo shops impacted by Canadian tariffs, supplier stops shipment to U.S.

BUFFALO, N.Y. (WKBW) — For years, tattoo shops in Western New York relied on Eikon, a Canadian tattoo supply company. Eikon recently stopped shipping to the United States due to recent tariffs. "Eikon was a main place to order for a long time," said Jeffrey Bagneschi, of North Star Tattoo.

7 News WKBW

Oct

27th

2025

17:46

CT_Monitor Company

EIK1001 Plus Pembrolizumab/Chemo ORR 64% in 1L Stage IV NSCLC

Adding the toll-like receptor (TLR) 7/8 coagonist EIK1001 to pembrolizumab (Keytruda) and chemotherapy yielded an objective response rate (ORR) of 64% (95% CI, 49%-77%) as first-line therapy in 50 evaluable patients with stage IV non–small cell lung cancer (NSCLC), according to data from the phase 2 TeLuRide-005 trial (NCT06246110) that were presented at the 2025 ESMO Congress.

Targeted Oncology

Oct

20th

2025

16:45

CT_Monitor Company

Frontline EIK1001 Plus Chemoimmunotherapy Stimulates Antitumor Activity in Advanced NSCLC

The addition of the toll-like receptor (TLR) 7/8 coagonist EIK1001 to pembrolizumab (Keytruda) and chemotherapy produced an objective response rate (ORR) of 64% (95% CI, 49%-77%) as first-line therapy in 50 evaluable patients with stage IV non–small cell lung cancer (NSCLC), according to data from the phase 2 TeLuRide-005 trial (NCT06246110) that were presented at the 2025 ESMO Congress .

OncLive

Sep

16th

2025

13:54

Events

MLA calls for manufacturing strategy as conference panel highlights finance and funding challenges for sector

Speaking following a panel debate on finance and funding at the Eikon Exhibition Centre, Alliance party MLA for Lagan Valley Honeyford said the scale of innovation and ambition on display from local firms underlined why Northern Ireland cannot afford to fall behind international competitors.

Belfast News Letter

Sep

10th

2025

10:33

Climate Transition Risk, ESG Rating Divergence and Portfolio Performance: Evidence From Composite Scores and Climate‐Adjusted Factor Models

ABSTRACT This study investigates how ESG rating divergences and climate transition risks jointly influence portfolio performance. Using a newly constructed composite Environmental (E) score derived from principal component analysis (PCA) across three leading ESG providers (Eikon, RobecoSAM, Sustainalytics), we build industry‐adjusted portfolios for 389 US firms across 10 sectors, including agriculture and industrial sectors.

Wiley Online Library

Sep

9th

2025

01:55

Events, CT_Monitor Company

Leading industry figures to take to stage at NI Manufacturing and Supply Chain Conference

Key industry figures from across the country have been confirmed as speakers for the upcoming Northern Ireland Manufacturing and Supply Chain Conference & Exhibition, taking place at the Eikon Exhibition Centre this Thursday (Sept 11). Sign up to our daily Derry Journal Today newsletter Sign up Thank you for signing up! Did you know with an ad-lite subscription to Derry Journal, you get 70% fewer ads while viewing the news that matters to you.

Derry Journal

Jul

7th

2025

00:17

Franz Richter Confirmed as Meyer Burger's Member of Directors Board

MEYER BURGER TECHNOLOGY AG MBTN : SAID ON FRIDAY: FRANZ RICHTER CONFIRMED AS MEMBER OF THE BOARD OF DIRECTORS OF MEYER BURGER APPOINTMENT VALID UNTIL 30 JUNE 2026 SUBJECT TO POTENTIAL EARLIER RE-ELECTION OR DISMISSAL

TradingView

Jun

5th

2025

18:30

LES ACTIONS AMÉRICAINES EN MOUVEMENT-Mineurs d'or, Boeing, GameStop

((Traduction automatisée par Reuters à l'aide de l'apprentissage automatique et de l'IA générative, veuillez vous référer à l'avertissement suivant: https://bit.ly/rtrsauto)) * Chaîne de recherche Eikon pour les mouvements de titres individuels: STXBZ * Bulletin d'information

Boursorama

May

29th

2025

19:10

Events,

Eikon Therapeutics to Share Clinical Data and Program Updates at the 2025 ASCO Annual Meeting

Eikon Therapeutics to Share Clinical Data and Program Updates at the 2025 ASCO Annual Meeting Eikon Therapeutics, Inc., a late-stage clinical biopharmaceutical company dedicated to integrating advanced engineering with traditional biology research to accelerate drug discovery, today announced that new data from its oncology programs will be presented in collaboration with independent investigators at the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 30 ? June 3, 2025, in Chicago, Illinois.

Le Lézard

May

26th

2025

16:44

New Offerings, Cost Cutting,

Updated: Eikon Therapeutics cuts staff for the second time in less than two years

Eikon Therapeutics is laying off staff for the second time in 19 months, responding to “changes in external circumstances” that have created “financial challenges.” … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Endpoints

EIKON Group's customers primarily consist of consumer electronics and entertainment Providers companies. Examples of EIKON Group's customers include Paramount Global, Apple and The Walt Disney Company.

Analysis

Data

Analysis

Data

EIKON Group

2024 Revenue

Founded

Headcount

Headquarters

Primary Segment

Ownership

Deployments

News Summary:

Similar Companies

Example Customers

Analyst insight reports